- Home
- PDEX vs GLSI Comparison
PDEX vs GLSI Comparison
Compare PDEX & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDEX
- GLSI
- Stock Information
- Founded
- PDEX 1978
- GLSI 2006
- Country
- PDEX United States
- GLSI United States
- Employees
- PDEX N/A
- GLSI N/A
- Industry
- PDEX Medical/Dental Instruments
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- PDEX Health Care
- GLSI Health Care
- Exchange
- PDEX Nasdaq
- GLSI Nasdaq
- Market Cap
- PDEX 152.3M
- GLSI 149.5M
- IPO Year
- PDEX N/A
- GLSI 2020
- Fundamental
- Price
- PDEX $36.39
- GLSI $11.00
- Analyst Decision
- PDEX Strong Buy
- GLSI Strong Buy
- Analyst Count
- PDEX 1
- GLSI 1
- Target Price
- PDEX $56.00
- GLSI $39.00
- AVG Volume (30 Days)
- PDEX 35.5K
- GLSI 41.5K
- Earning Date
- PDEX 10-30-2025
- GLSI 08-14-2025
- Dividend Yield
- PDEX N/A
- GLSI N/A
- EPS Growth
- PDEX 345.00
- GLSI N/A
- EPS
- PDEX 2.67
- GLSI N/A
- Revenue
- PDEX $66,593,000.00
- GLSI N/A
- Revenue This Year
- PDEX $7.22
- GLSI N/A
- Revenue Next Year
- PDEX N/A
- GLSI N/A
- P/E Ratio
- PDEX $13.58
- GLSI N/A
- Revenue Growth
- PDEX 23.68
- GLSI N/A
- 52 Week Low
- PDEX $23.45
- GLSI $8.06
- 52 Week High
- PDEX $70.26
- GLSI $16.50
- Technical
- Relative Strength Index (RSI)
- PDEX 33.31
- GLSI 42.85
- Support Level
- PDEX $35.05
- GLSI $10.87
- Resistance Level
- PDEX $47.81
- GLSI $11.89
- Average True Range (ATR)
- PDEX 2.36
- GLSI 0.52
- MACD
- PDEX -1.03
- GLSI -0.14
- Stochastic Oscillator
- PDEX 10.00
- GLSI 18.43
About PDEX Pro-Dex Inc.
Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.